# BETA BIONICS, INC. (BBNX) · Edgar & Edgarette company card

> Beta Bionics (BBNX) grew revenue 53.9% in FY2025 to $100 million, operating margin -71.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 87.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1674632 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/BBNX) · [JSON](https://www.pops4.com/boards/company/BBNX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $100M |
| Revenue growth, 1 year | 53.9% |
| Revenue growth per year | 188.9% |
| Operating margin | -71.5% (prior year -69.5%) |
| Net margin | -73.0% |
| Operating cash flow | −$51M |
| Capital spending | $5M |
| Free cash flow | −$56M |
| Cash | $32M |
| Long-term debt | — |
| Total assets | $329M |
| Total equity | $288M |
| Equity ÷ assets | 87.5% |
| Return on equity | -25.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.94 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -1.86 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -71.5% in FY2025

## Edgarette's reading

Exposure: revenue $100.3M (FY2025). Experience: revenue up 53.9% on the year, up 188.9% a year over 2 years; operating margin -71.5%, down from -69.5%. Soundness: equity 87.5% of assets, return on equity -25.5%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $175.1M and $281.4M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -71.5% against a 1.2% median; growth 53.9% against 11.6%.

Range logged 2026-09-20, receipt 30c4f351ae15f3fc, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-10-27 · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000167463226000003/0001674632-26-000003-index.htm)
- 8-K · filed 2026-10-27 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000117184326006856/0001171843-26-006856-index.htm)
- 8-K · filed 2026-09-17 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000119312526393322/0001193125-26-393322-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000119312526392088/0001193125-26-392088-index.htm)
- 10-Q · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000119312526323777/0001193125-26-323777-index.htm)
- 8-K · filed 2026-07-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/0001171843-26-005010-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001674632.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674632

## Cite

POPS4, Edgar & Edgarette: BETA BIONICS, INC. (BBNX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BBNX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.